NASDAQ:CAPR
Capricor Therapeutics Stock Signals
Latest Data & Signals Issued
| Signal Type | Signal Value | Data | |
|---|---|---|---|
| Score | -2.915 | 1 day ( 0 % ) | |
| Last Price | $4.12 | -1.67 % | |
| High/ Low | $4.06 - $4.27 | 0.246% | |
| Chg 7 Days | -5.07 % | $4.34 $4.12 | |
| Chg 30 Days | -4.19 % | $4.30 $4.12 | |
| Chg 12 mos | -22.70 % | $5.33 $4.12 | |
| Trend - 3 mos | 16.77 % | Width: 27.48 % | |
| Trend - 12 mos | 13.43 % | Width: 94.48 % | |
| Pred. range - 3 mos | $4.80 - $6.12 | 16.57 % - 48.61 % | |
| Pred. range - 12 mos | $4.03 - $7.85 | -2.09 % - 90.42 % | |
| Short mv avg 3 mos | Sell | 2023-03-06 - 15 days | |
| Long mv avg 3 mos | Sell | 2023-03-16 - 7 days | |
| Short/Long mv avg 3 mos | Sell | 2023-03-22 - 3 days | |
| Short mv avg 12 mos | Sell | 2023-03-08 - 13 days | |
| Long mv avg 12 mos | Sell | 2023-03-21 - 4 days | |
| Short/Long mv avg 12 mos | Buy | 2023-03-02 - 17 days | |
| Pivot Short | Sell | 2023-03-01 - 18 days | |
| Bollinger | Buy | 2023-03-24 - 1 day | |
| MACD | Sell | No Dates Stored For This Signal |
About Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph... CAPR Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
